trial

Early Intervention of Prodromal Schizophrenia Using an NMDA Enhancer

NCTId NCT05052853
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2 · Recruiting
Enrollment 48 (estimated)
Sponsored by China Medical University Hospital
Primary completion 2026-10
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2
Status
Recruiting
Enrollment
48 (estimated)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Triple
Start
2021-11-01
Primary completion
2026-10
Eligibility
ALL · 13 Years · 45 Years

Interventions & indications

Drugs
NMDAE

Sponsors

China Medical University HospitalLead Sponsor

Sites

1 total
Taichung, Taiwan

Linked catalysts

1
Early Intervention of Prodromal Schizophrenia Using an NMDA Enhancer — primary completion2026-10

Facts & assertions

4 sourced
Enrollment
48
Phase
PHASE2
Primary Completion Date
2026-10
Status
RECRUITING
relationships
The graph out of here
drug
NMDAE
drug
lead_sponsor
China Medical University Hospital
company
indication
Prodromal Schizophrenia
indication
Schizophrenia
indication
Schizotypal Personality Disorder
indication